Passage Bio, Inc. PASG
3.45 USD +0.13 (+3.92%)
Nov 3, 2026, 3:22 PM EST
3.33 Day range 3.47
3.29 52-week range 20.00
- YTD
- -70.76%
- 1 year
- -52.87%
Analyst view
Price target (mean) 8.00 +131.9% upside
Now 3.45
- Target (low)
- 4.00
- Target (mean)
- 8.00
- Target (high)
- 13.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24 | -0.24 – -0.24 | -0.30 | +20.0% | 0 | 0.0% | 1 |
| Next quarter | -0.25 | -0.25 – -0.25 | -0.30 | +16.7% | 0 | 0.0% | 1 |
| Current year | -1.11 | -1.11 – -1.11 | -1.77 | +37.1% | 0 | 0.0% | 1 |
| Next year | -0.54667 | -1.00 – -0.30 | -1.11 | +50.7% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 14, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 17, 2024 | Canaccord Genuity | Reiterated | Buy | Buy |
| Sep 3, 2024 | Rodman & Renshaw | Initiated | — | Buy |
| May 15, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 5, 2024 | Canaccord Genuity | Reiterated | Buy | Buy |
| Nov 14, 2023 | Raymond James | Maintained | Outperform | Outperform |
| Aug 8, 2023 | Chardan Capital | Maintained | Buy | Buy |
| May 12, 2023 | Raymond James | Maintained | Outperform | Outperform |
| Dec 15, 2022 | Chardan Capital | Maintained | — | Buy |
| Nov 11, 2022 | Guggenheim | Maintained | — | Buy |
| Nov 11, 2022 | Citigroup | Maintained | — | Buy |
| Nov 8, 2022 | Canaccord Genuity | Initiated | — | Buy |
| May 17, 2022 | Citigroup | Maintained | — | Buy |
| May 17, 2022 | Raymond James | Maintained | — | Outperform |
| Mar 8, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 4, 2022 | Raymond James | Maintained | — | Outperform |
| Jan 19, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Jul 1, 2021 | Raymond James | Initiated | — | Outperform |
| Jun 15, 2021 | BTIG | Initiated | — | Buy |
| Mar 8, 2021 | Chardan Capital | Maintained | — | Buy |
| Mar 4, 2021 | Goldman Sachs | Upgrade | Neutral | Buy |
| Feb 4, 2021 | Guggenheim | Initiated | — | Buy |
| Jan 4, 2021 | JP Morgan | Upgrade | Neutral | Overweight |
| Dec 11, 2020 | Citigroup | Initiated | — | Neutral |
| Aug 14, 2020 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 25, 2020 | Goldman Sachs | Downgrade | Buy | Neutral |
| May 11, 2020 | Chardan Capital | Maintained | — | Buy |
| Mar 25, 2020 | Chardan Capital | Initiated | — | Buy |
| Mar 24, 2020 | Goldman Sachs | Initiated | — | Buy |